Jan 09, 2024 / 05:45PM GMT
Anupam Rama - JPMorgan Chase & Co, Research Division - VP and Analyst
Welcome, everyone, to the 42nd Annual JPMorgan Healthcare Conference. My name is Anupam Rama, I'm one of the senior Biotech Analysts here at JPMorgan. I'm joined by my squad, [Lorea] Hall, Malcolm Kuno, and Priyanka Grover.
Our next presenting company is Neurocrine, and presenting on behalf of the company, we have CEO, Kevin Gorman. Kevin?
Kevin C. Gorman - Neurocrine Biosciences, Inc. - CEO & Director
Thank you, Anupam, and welcome, everyone. I want to say a big thanks to Anupam and the JPMorgan team for the opportunity to be here today. We -- I will be making forward-looking statements, so I direct you to our more most recent SEC guidelines.
So Neurocrine is a company that has traditionally taken on drug development in areas that have never had drug development before. And I think that, that -- when I show you our pipeline or commercial activities, you'll see that to be true.
And that is something that we feel passionately about. It's not that we -- all
Neurocrine Biosciences Inc at JPMorgan Healthcare Conference Transcript
Feb 08, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers